Point72 Asset Management
BLTE

Point72 Asset Management’s Belite Bio BLTE Stock Holding History

Point72 Asset Management’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-284,437
Closed -$45.5M – 3804
2025
Q4 		$45.5M Buy
284,437
+281,337
+9,075% +$33.3M 0.05% 448
2025
Q3 		$229K Buy
3,100
+1,800
+138% +$118K ﹤0.01% 2111
2025
Q2 		$75K Buy
+1,300
New +$79.3K ﹤0.01% 2088
2024
Q4 		– Sell
-4,800
Closed -$225K – 2092
2024
Q3 		$225K Sell
4,800
-2,511
-34% -$122K ﹤0.01% 1765
2024
Q2 		$334K Sell
7,311
-1,389
-16% -$60.1K ﹤0.01% 1521
2024
Q1 		$334K Buy
8,700
+1,000
+13% +$44.8K ﹤0.01% 1753
2023
Q4 		$352K Buy
+7,700
New +$296K ﹤0.01% 1664

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management's BLTE Position: Q1 2026 in Review

Point72 Asset Management sold out of Belite Bio (BLTE) in Q1 2026, closing a stake of 284,437 shares — an estimated $45.5M sold.

Point72 Asset Management first reported a position in BLTE in Q4 2023 and held it in 7 quarters. The position peaked at $45.5M in Q4 2025. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • Point72 Asset Management reported no remaining Belite Bio position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 284,437 Belite Bio shares in Q1 2026, an estimated $45.5M.
  • Point72 Asset Management first reported a position in Belite Bio in Q4 2023 and held it in 7 quarters.
  • Point72 Asset Management's Belite Bio position peaked at $45.5M in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.